Form 4: Ionis Pharmaceuticals EVP Sells Shares

Ionis Pharmaceuticals EVP Eric Swayze reported a sale of 10,602 shares of common stock on June 25, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals Inc., sold 10,602 shares of common stock on June 25, 2026.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026.
• The weighted average sale price was $79.1824, with individual transactions ranging from $79.00 to $79.46.
• Following the transaction, Swayze beneficially owns 21,759 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, although it was conducted under a pre-planned trading strategy.

Negatives

• Executive Vice President of Research sold a significant number of shares (10,602).

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for executives to diversify holdings or manage personal finances. However, the volume and timing relative to company news can be a factor for investors to consider.

Stakeholder Impact

• Shareholders may view the sale by a key executive as a potential signal, though the Rule 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Eric Swayze, Beneficial Ownership